Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.78 |
| ▸ | ALB | P02768 | 1/20 | 0.72 |
| ▸ | IL2 | P60568 | 1/20 | 0.72 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.70 |
| ▸ | CCKAR | P32238 | 1/20 | 0.62 |
| ▸ | CCKBR | P32239 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160275 | 1.00 | PYGL (0.78) | PYGLALBIL2CYP51A1CCKAR | |
| SCHEMBL7971407 | 0.87 | CCKAR (0.79) | PYGLALBIL2CYP51A1CCKAR | |
| SCHEMBL6163462 | 0.86 | PYGL (0.76) | PYGLCCKARCCKBR | |
| SCHEMBL6162503 | 0.86 | PYGL (1.00) | PYGLCYP51A1 | |
| SCHEMBL6163466 | 0.86 | PYGL (0.76) | PYGLCCKARCCKBR | |
| SCHEMBL6345409 | 0.85 | PYGL (0.65) | PYGLALBIL2CYP51A1 | |
| SCHEMBL6353073 | 0.85 | PYGL (0.65) | PYGLALBIL2CYP51A1 | |
| SCHEMBL6162694 | 0.85 | PYGL (0.71) | PYGLALBIL2CYP51A1 | |
| SCHEMBL6162698 | 0.85 | PYGL (0.71) | PYGLALBIL2CYP51A1 | |
| SCHEMBL2735826 | 0.85 | EGFR (0.76) | PYGLALBIL2CYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134213-B1 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0832065-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1134213-A2 | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides | PFIZER INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6277877-B1 | GLYCOGEN PHOSPHORYLASE INHIBITOR; ANTIDIABETIC AGENTS | PFIZER, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6107329-A | HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | PFIZER, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0832065-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1142492-A | Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents | PFIZER (US) | 1997-02-12 | — | — | CN | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |